HealthPharma & Biotech

AstraZeneca’s new Japanese cancer drug tipped to rack up billions in annual sales

Liberum thinks trastuzumab deruxtecan can generate peak sales of more than US$3bn, given the drug’s potential in a host of cancer indications

A first regulatory submission for the drug is due later this year

AstraZeneca PLC’s (LON:AZN) recent tie-up with a Japanese drug developer could add billions to its top-line, according to analysts at Liberum.

Last week, the FTSE 100-pharma giant announced the UK’s biggest cash call so far this year, raising US$3.5bn to help fund its collaboration with Daiichi Sankyo.

The pair are working together to develop trastuzumab deruxtecan, a potential breakthrough treatment for HER-2 positive strains of cancer, such as certain forms of breast and gastric cancers.

READ: AstraZeneca launches UK’s biggest cash call to fund Japanese cancer deal

Trastuzumab deruxtecan isn’t approved for use yet, but the first regulatory submission is scheduled for later this year as a treatment for patients with advanced or hard-to-treat breast cancer.

City broker Liberum expects it to get the thumbs-up from regulators, after which analysts reckon it will go on to rack up billions of dollars in sales every year.

“We have looked at the sales potential of this drug in HER2+ cancers,” read a note to clients.

“It should be a blockbuster drug in its first indication, and has every chance of reaching US$3bn+ in sales globally.

“However, the real value in this deal will only be visible in earnings after 2023 when clinical trials open up larger patient populations.”

Liberum repeated its ‘hold’ recommendation but upped its price target to 6,400p.

In early morning trading, Astra shares were down 0.3% to 6,098p.

Quick facts: AstraZeneca

Price: £71.23

Market: LSE
Market Cap: £929.91 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Full interview: hVIVO PLC's 2020 pipeline 'looking strong' as it expands...

hVIVO PLC's (LON:HVO) executive chairman Trevor Phillips tells Proactive London's Andrew Scott the business is now better positioned to be profitable next year. The creator of pioneering human disease models based upon viral challenge generated revenues of £5.9mln in the six months ended June...

4 hours, 41 minutes ago

2 min read